Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

Key Points: Question: Is fovinaciclib plus letrozole or anastrozole effective and safe as first-line treatment in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (ERBB2; formerly HER2)–negative advanced breast cancer? Findings: This phase 3 randomized clinical trial...

Descripción completa

Detalles Bibliográficos

Publicado en:	JAMA Oncology Vol. 12; no. 8; pp. 855 - 863
Autores principales:	Yuan, Peng, Liu, Yunjiang, Li, Wei, Li, Huiping, Tong, Zhongsheng, Cheng, Jing, Zhang, Mingjuan, Shan, Jinlu, Zhong, Jincai, Yi, Tienan, Liu, Jian, Li, Huihui, Huang, Zhen, Wu, Jinsheng, Ding, Sijuan, Li, Liang, Zong, Hong, Jia, Hongyan, Wang, Shusen, Wang, Kun
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	American Medical Association Aug2026
Acceso en línea:	Ver este registro en EBSCOhost